Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn’s Disease: A Retrospective Cohort Study
Keyword(s):
Abstract Background This study clarifies the long-term effectiveness of ustekinumab based on real-life data from Japanese Crohn’s disease (CD) patients. Methods A total of 137 patients were included, and 124 patients (90.5%) were exposed to anti-tumor necrosis factor-α agents. Results The clinical remission rate at week 52 was 32.4% in moderate to severely active CD patients. The achievement of clinical remission for 8 weeks after ustekinumab therapy induction was associated with clinical remission at week 52. Ustekinumab persistence rate at week 104 was 81.4%. Conclusion Ustekinumab is effective and persistent in CD patients with the previous treatment history of several biologics.
2020 ◽
Vol 14
(Supplement_1)
◽
pp. S118-S120
◽
Keyword(s):
2020 ◽
Vol 14
(Supplement_1)
◽
pp. S379-S379
Keyword(s):
2021 ◽
Vol 15
(Supplement_1)
◽
pp. S536-S537
2020 ◽
Vol 14
(Supplement_1)
◽
pp. S381-S382
Keyword(s):
2020 ◽
Vol 14
(Supplement_1)
◽
pp. S347-S348
Keyword(s):
2021 ◽
Vol 15
(Supplement_1)
◽
pp. S400-S401
Keyword(s):
2020 ◽
Vol 14
(Supplement_1)
◽
pp. S329-S330
Keyword(s):